Search
vilobelimab (Gohibic)
Indications:
- hospitalized patients with severe COVID-19 within 48 hours of starting mechanical ventilation or extracorporeal membrane oxygenation
* FDA-approved for Emergency Use Authorization
Mechanism of action:
- anti-C5a monoclonal antibody that targets an inflammatory pathway believed to be involved in COVID-19 progression
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
antiviral agent
References
- Harris E
FDA Approves Vilobelimab for Emergency Use in Hospitalized Adults.
JAMA. Published online April 19, 2023.
https://jamanetwork.com/journals/jama/fullarticle/2804233